PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against StubHub Holdings, Inc. (NYSE: STUB) (“StubHub” or the “Company”) on behalf of investors who purchased or otherwise acquired StubHub securities during the period of September 14, 2025 through November 24, 2025 (the “Class Period”), including shares issued pursuant and/or traceable to StubHub’s September 2025 initial public offering (“IPO”). Investor Dea ...

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities [3]. Group 2: Allegations Against Ardent Health - Ardent Health operates acute care hospitals and healthcare facilities, with a critical focus on the collection of accounts receivable [4]. - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections," while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million decrease in revenue for the quarter and increased its professional liability reserves by $54 million due to adverse claim developments [5]. - Following this announcement, Ardent Health's stock price dropped by $4.75 per share, or over 33%, from $14.05 to $9.30 per share [5].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and failed to disclose critical information about accounts receivable and liability reserves, leading to significant financial losses for investors during the specified class period [1][3][4]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, which allowed the company to report inflated financial figures [3]. - A significant decrease of $43 million in third quarter 2025 revenue was revealed, attributed to revised assessments of accounts receivable collectability after a transition to a new revenue accounting system [4]. - The company cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million – $615 million to $530 million – $555 million, due to ongoing industry-wide cost pressures [4]. Group 2: Professional Liability Concerns - Ardent Health allegedly did not maintain sufficient professional malpractice liability insurance to cover potential claims, which raises concerns about its financial stability [3]. - The lawsuit indicates that the company recorded a $54 million increase in professional liability reserves due to recent settlements and ongoing litigation, reflecting broader industry trends and social inflationary pressures [4]. Group 3: Legal Process and Representation - Investors who purchased Ardent Health securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [5]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having secured over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - The Varonis Systems, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth potential, leading to significant stock price declines following disappointing financial results [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Molchanov v. Varonis Systems, Inc., and it involves purchasers of Varonis common stock from February 4, 2025, to October 28, 2025 [1]. - Investors have until March 9, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Varonis and its executives violated the Securities Exchange Act of 1934 by providing false information about the company's financial health [3]. Group 2: Allegations Against Varonis - The lawsuit claims that Varonis misrepresented its ability to maintain revenue growth and downplayed risks associated with seasonality and macroeconomic factors [3]. - On October 28, 2025, Varonis reported third-quarter results that significantly missed projections, leading to a nearly 49% drop in stock price [4]. - CEO Yakov Faitelson attributed the shortfall to lower renewals in both Federal and non-Federal subscription businesses during the final weeks of the quarter [4]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Varonis stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can choose a law firm to litigate the case [5]. - Participation as a lead plaintiff does not affect an investor's ability to share in any potential recovery from the lawsuit [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years [6]. - Robbins Geller has a significant history of obtaining large recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].

Core Viewpoint - The article discusses a pending securities class action lawsuit against Stride, Inc. (NYSE: LRN) related to alleged fraudulent practices that led to significant investor losses, with a focus on the deadline for investors to join the lawsuit as lead plaintiffs [1][9]. Group 1: Allegations of Fraud - The lawsuit claims that Stride engaged in two fraudulent schemes: inflating enrollment figures through "Ghost Students" and failing to disclose a critical technology platform failure [2][5]. - The alleged enrollment fraud involved retaining "Ghost Students" to artificially inflate metrics, which reportedly led to an 11% stock drop upon initial disclosure [6]. - The concealed technology failure blocked access for approximately 10,000 to 15,000 students, resulting in a forecasted sales growth decline from 19% to only 5%, contributing to a 54% stock crash in a single day [7][8]. Group 2: Financial Impact - The cumulative impact of the fraudulent disclosures resulted in a loss of billions in market capitalization for Stride [2]. - The stock price fell by 54% on the day the severity of the platform failure was revealed, indicating a drastic correction in the market's perception of Stride's financial health [4][8]. Group 3: Legal Proceedings - The complaint seeks to recover losses for investors who purchased LRN securities during the Class Period from October 22, 2024, to October 28, 2025, holding Stride and its executives accountable for alleged misrepresentations [9]. - Hagens Berman, the law firm leading the case, emphasizes the systematic nature of the alleged fraudulent practices and is actively gathering evidence to support the claims [4][10].

Core Viewpoint - Hagens Berman alerts investors in Primo Brands Corporation regarding a deadline for lead plaintiff appointment in a securities class action lawsuit related to undisclosed operational issues following the merger with BlueTriton Brands [1][5]. Group 1: Allegations and Lawsuit Details - The lawsuit aims to recover losses incurred by investors after the revelation of a severe operational crisis that was allegedly concealed by the company [2]. - The complaint claims that management misrepresented the merger integration as "flawless," while the reality involved significant failures in technology, logistics, and customer service [2][4]. - The first major disclosure occurred on August 7, 2025, when the company reported weak Q2 results and reduced guidance, leading to a 9% drop in stock price [6]. - The final disclosure on November 6, 2025, involved a drastic reduction in full-year adjusted EBITDA guidance and the replacement of the CEO, resulting in a 21% stock crash [3][6]. Group 2: Management and Operational Issues - The crux of the complaint centers on the contradiction between the company's assurances of a successful merger and the new CEO's acknowledgment of "self-inflicted" disruptions affecting the ReadyRefresh delivery business [4]. - The litigation highlights undisclosed operational risks masked by the company's misrepresentations regarding the merger integration [4]. Group 3: Next Steps for Investors - Investors who purchased PRMB shares during the Class Period (June 17, 2024 – November 6, 2025) and experienced significant losses are encouraged to contact Hagens Berman for assistance [5]. - The deadline for submitting claims to become a lead plaintiff is January 12, 2026 [1][6].

Core Viewpoint - The Fermi Inc. class action lawsuit alleges that the company and its executives made misleading statements regarding its Project Matador, leading to significant financial losses for investors following the termination of a key funding agreement [3][4][5]. Company Overview - Fermi Inc. is characterized as an energy and AI infrastructure company that conducted its initial public offering (IPO) in October 2025, selling 37,375,000 shares at a price of $21.00 per share [2]. Allegations of Misconduct - The lawsuit claims that Fermi overstated tenant demand for its Project Matador campus and failed to disclose reliance on a single tenant's funding commitment, which posed a risk of termination [3]. - It is alleged that the company did not adequately inform investors about the significant risk associated with the tenant's funding commitment [3]. Impact of the Lawsuit - Following the announcement that the first tenant for Project Matador had terminated a $150 million funding agreement, Fermi's stock price dropped nearly 34% [4]. - The stock price has reportedly fallen to as low as $8.59 per share, representing a 59% decline from the IPO price [5]. Legal Process - Investors who purchased Fermi common stock during the IPO or the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 18, 2024, to November 12, 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health's Q3 2025 revenue was overstated due to inadequate assessments of accounts receivable collectability following a transition to a new revenue accounting system [3]. - The company's 2025 EBITDA guidance was allegedly overstated and would be reduced by $57.5 million at the midpoint, approximately 9.6%, due to persistent industry-wide cost pressures, including payer denials [3]. - As a result, statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Investor Actions and Legal Representation - Investors who suffered losses in Ardent have until March 9, 2026, to request the Court to appoint them as lead plaintiff, although sharing in any recovery does not require serving as lead plaintiff [4]. - Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors nationwide, emphasizing their commitment to restoring investor capital and ensuring corporate accountability [6].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Company Overview - Ardent Health operates acute care hospitals and healthcare facilities, with a focus on the collection of accounts receivable [4]. Allegations of Misrepresentation - The lawsuit claims that Ardent Health misrepresented its process for determining the collectability of accounts receivable, stating it relied on "detailed reviews of historical collections," while in reality, it used a "180-day cliff" method, leading to inflated accounts receivable figures [4]. Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease and a $54 million increase in professional liability reserves, resulting in a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5]. Legal Proceedings - Investors have until March 9, 2026, to request to lead the case in the U.S. District Court for the Middle District of Tennessee, under the caption Postiwala v. Ardent Health, Inc., et al. [3]. Legal Representation - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing the plaintiffs, with a history of recovering significant amounts for investors [7].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the actual decline in demand and revenue from these products [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].